Scinai Immunotherapeutics Ltd ADR(SCNI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 22 at 5:06 AM ET (Korea 10/22 18:06)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -47.55 | Insider Own | 2.25% | Shs Outstand | 0.7M | Perf Week | -30.66% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.7M | Perf Month | -68.05% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 2.69% | Short Float | 2.88% | Perf Quarter | -75.31% |
| Income | -0.00B | P/S | 0.29 | EPS this Y | - | Inst Trans | 123.46% | Short Ratio | 0.01 | Perf Half Y | -88.76% |
| Sales | 0.00B | P/B | 0.06 | EPS next 5Y | - | ROA | -18.38% | Short Interest | 0.02M | Perf YTD | -91.43% |
| Book/sh | 10.71 | P/C | 0.15 | EPS past 3/5Y | 51.07% 21.04% | ROE | -27.22% | 52W High | -96.06% ($15.50) | Perf Year | -95.96% |
| Cash/sh | 4.01 | P/FCF | - | Sales past 3/5Y | - | ROIC | -17.84% | 52W Low | -7.55% ($0.66) | Perf 3Y | -99.13% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -165.46% | Gross Margin | - | Volatility(W/M) | 19.25% 15.23% | Perf 5Y | -99.97% |
| Dividend TTM | - | EV/Sales | 4.53 | Sales Y/Y TTM | 30.12% | Oper. Margin | -435.17% | ATR (14) | 0.22 | Perf 10Y | -99.98% |
| Dividend Ex-Date | - | Quick Ratio | 1.56 | EPS Q/Q | 79.16% | Profit Margin | -178.14% | RSI (14) | 25.69 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.56 | Sales Q/Q | 144.95% | SMA20 | -47.66% ($1.17) | Beta | 2.19 | Target Price | $7000 |
| Payout | - | Debt/Eq | 0.31 | Earnings | 2026/8/24 | SMA50 | -66.22% ($1.81) | Rel Volume | 0.09 | Prev Close | $0.68 |
| Employees | 45 | LT Debt/Eq | 0.27 | EPS/Sales Surpr. | - | SMA200 | -87.1% ($4.73) | Avg Volume(3M) | 2.11M | Price | $0.61 |
| IPO | 2015/5/12 | Option/Short | No/Yes | Trades | 486 | Volume | 186,993 | Change | -10.44% |
🧬 This is an Israeli biotech company developing biopharmaceuticals for inflammatory and immune diseases, while also providing CDMO services. The company is pursuing revenue diversification through its proprietary development pipeline and contract manufacturing business.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded less than usual. That is 9% of its average volume.
SCNI has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $29. Peers typically go for $1,173.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
RACK VanEck Data Center Supply Chain ETF <0.01% 
SPDW State Street SPDR Portfolio Developed World ex-US ETF <0.01% It ranks #593 of 595 in the industry
Based on market cap of $0M.
LABT#590 Lakewood-Amedex Biotherapeutics Inc $1M PER - 
CRIS#591 Curis Inc $1M PER - 
SPRC#592 SciSparc Ltd $1M PER - SCNI#593 Scinai Immunotherapeutics Ltd ADR $0M PER - 
BDRX#593 Biodexa Pharmaceuticals Plc ADR $0M PER - 
FAQ
What kind of company is SCNI?
SCNI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SCNI?
The market cap of SCNI is approximately $0M, ranking 5,885 within its sector.
What is the 52-week high and low for SCNI?
SCNI has recorded a 52-week high of $15.50 and a low of $0.66.
